ANTIMICROBIAL SUSCEPTIBILITY OF Streptococcus agalactiae ISOLATED FROM PREGNANT WOMEN

Abstract

SUMMARYIntroduction:Group B streptococcus (GBS) or Streptococcus agalactiae can colonize the gastrointestinal and genitourinary tracts and has been considered one of the most important risk factors for the development of neonatal disease. The present study evaluated the antimicrobial susceptibility of GBS isolates from pregnant women who were attended at a public health service in Northern Paraná, Brazil. Methods:A descriptive analytical cross-sectional study was performed with 544 pregnant women, at ≥ 35 weeks of gestation. One hundred and thirty-six GBS isolates from pregnant women were tested for antimicrobial susceptibility. Results:All of the GBS isolates showed susceptibility to the drug that is most frequently used for intrapartum prophylaxis: penicillin. Resistance to clindamycin and erythromycin was detected, thus decreasing the options of prophylaxis in women who are allergic to penicillin. Conclusions: Additional studies should be conducted to increase the knowledge of GBS sensitivity profile to antimicrobials in other health centers.

Antibiotic prophylaxis in preterm rupture of membranes

“…The combination ampilicillin-sulbactam followed by amoxicillin-clavulanate vs. cefazolin-cephalexin associated with erythromycin was evaluated retrospectively by Ehsanipoor et al 23 The main objective of the study was to determine whether the use of amoxicillin-clavulanate was associated with increased cases of necrotizing enterocolitis. In contrast to previous results, 16 they showed no increased risk in infants exposed to amoxicillin-clavulanate (8 vs. 10.2%, p = 0.64) and no other findings related to maternal or neonatal morbidity. Even with their reduced sampling, the authors suggest that ampicillin-sulbactam associated with amoxicillin-clavulanate and a cephalosporin associated with erythromycin are safe and effective antibiotic regimens for patients with PPROM.…”

Semina: Ciências Biológicas e da Saúde, Londrina, v. 39, n.1, jan./jun. 2018

“…Similar rates of erythromycin and clindamycin resistance between GBS colonizer of pregnant women were detect in a Public Health Service of Maringá city in northern Paraná, Brazil. (27) Rates of resistance ranging from 0% to 14.3% and 7.7% to 12.2% for erythromycin and clindamycin, respectively were detected in studies performed in GBS isolated from pregnant women in Rio de Janeiro, Brazil. (32,33) In contrast, high rates of resistance for both antimicrobials were detected in other Brazilian studies (Table 3).…”

Antimicrobial resistance and molecular characterization of Streptococcus agalactiae from pregnant women in southern China

“…Based on the observation in the high resistance to erythromycin in our study, we proposed that erythromycin should not be a priority antibiotic choice for intrapartum GBS chemoprophylaxis. Notably, The American CDC guidelines no longer recommend erythromycin as a routine antimicrobial for the treatment of GBS infection [9]. Generally, antimicrobial therapy should be guided by the antimicrobial susceptibility test and necessity for the continuous monitoring of antimicrobial susceptibility profiles should also be emphasized, as well.…”

“…However, resistance to antimicrobials used as alternative therapy, especially macrolides, lincosamides and quinolones has been documented in different countries [4,8]. Erythromycin and clindamycin are given in cases in which there is a high risk of anaphylaxis to penicillin [9]. However, increasing resistance of GBS to erythromycin and clindamycin has been reported worldwide [10].…”